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Background: Status epilepticus (SE) is a frequent neurological emergency complicated by high mortality and often
poor functional outcome in survivors. The aim of this studywas to review available clinical scores to predict outcome.
Methods: Literature review. PubMed Search termswere “score”, “outcome”, and “status epilepticus” (April 9th 2015).
Publications with abstracts available in English, no other language restrictions, or any restrictions concerning investi-
gated patients were included.
Results: Two scores were identiﬁed: “Status Epilepticus Severity Score— STESS” and “Epidemiology based Mortality
score in SE— EMSE”. A comprehensive comparison of test parameters concerning performance, options, and limita-
tions was performed. Epidemiology basedMortality score in SE allows detailed individualization of risk factors and is
signiﬁcantly superior to STESS in a retrospective explorative study. In particular, EMSE is very good at detection of
good and bad outcome, whereas STESS detecting bad outcome is limited by a ceiling effect and uncertainty of correct
cutoff value. Epidemiology based Mortality score in SE can be adapted to different regions in the world and to ad-
vances in medicine, as new data emerge. In addition, we designed a reporting standard for status epilepticus to en-
hance acquisition and communication of outcome relevant data. A data acquisition sheet used from patient
admission in emergency room, from the EEG lab to intensive care unit, is provided for optimized data collection.
Conclusion: Status Epilepticus Severity Score is easy to perform and predicts bad outcome, but has a low predictive
value for good outcomes. Epidemiology basedMortality score in SE is superior to STESS in predicting good or bad out-
comebutneedsmarginallymore time toperform. EpidemiologybasedMortality score in SEmayproveveryuseful for
risk stratiﬁcation in interventional studies and is recommended for individual outcomeprediction. Prospective valida-
tion in different cohorts is needed for EMSE, whereas STESS needs further validation in cohorts with awider range of
etiologies.
This article is part of a Special Issue entitled “Status Epilepticus”.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Status epilepticus (SE) is a neurological emergency. Mortality rates
for convulsive SE vary from 7.6% to 39% in population-based studies
[1]. Many risk factors for death were reported as statistically signiﬁcant
group effects (for comprehensive review see [2]). However, group ef-
fects do not necessarily predict individual outcomes, which are needed
in clinical practice. Thus, data on group effects must be integrated intopilepticus outcome code; SLP,
gy, Christian Doppler Klinik,
r Straße 79, A-5020 Salzburg,
4.
er), e.trinka@salk.at (E. Trinka).
. This is an open access article underclinically useful scores to allow individual and fast risk assessment for
optimal patient management. In this regard, detection of bad outcome
is mandatory to avoid underdetection and undertreatment of SE.
Adequate detection of good outcome is necessary to minimize risks of
potentially harmful overtreatment and to assure economic use of re-
sources, e.g., intensive care unit admission. We performed a literature
search to identify all currently available scoring systems for outcome
prediction in status epilepticus.
2. Methods
We searched the PubMed database on April 9th 2015 for “score”,
“outcome”, and “status epilepticus” and their combinations for papers in
any language with abstracts available in English with no restrictions
concerning investigated patients.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Comparison of STESS and EMSE.
STESS [3–5] EMSE [6]
Number of parameters and total number of items to choose
4 (etiology, age, semiology, level of consciousness pretreatment), 9 items 4 (etiology, age, comorbidity, EEG), 45 items
Rationale for scoring points
A priori assumptions Epidemiological “real world” data: mortality rates of big studies (identiﬁed in
systematic reviews) were taken as scoring points. Different combinations of age,
etiology, etc., were tested for best performance.
Initial study
Retrospective evaluation (N = 107), then prospectively tested (N = 34) [3] Exploratory, hypothesis generating study, ﬁtting test/score to sample, N = 92
Prospective validation
Yes [4]: N = 154, Pending
First external validation
Yes [5]: N = 171: suggested change of threshold, s. below Pending
Cutoff indicating bad outcome (nonsurvival)
3 points or higher [3,4] OR 4 points or higher [5] 64 points or higher
Young patients with preexisting epilepsy (specialized epilepsy center with young patients with preexisting epilepsy)
No ceiling effect No ceiling effect
Elderly patients without preexisting epilepsy (general neurology, emergency room)
Ceiling effect, all pat. score high risk No ceiling effect
Flexibility for global use, e.g., developing countries
Minimal Yes
Adaptability as new epidemiological data emerge
Minimal Yes
Number of different items per parameter to individualize outcome prediction, remarks
Age
2 (below 65: 0 pt., 65 or higher: 2 pt.) 7 (for each decade: 21–30 a: 1 pt., 31–40 a: 2 pt., 41–50 a: 3 pt., 51–60 a: 5 pt.,
61–70 a: 7 pt., 71–80 a: 8 pt., N80 a: 10 pt.) [7]
Etiology
2 (previous seizures: 0 pt., no previous seizures: 1 pt.) 15 (etiologies [8,9]: CNS-anomalies: 2 pt.; drug reduction/withdrawal, poor compliance:
2 pt.; multiple sclerosis: 2 pt.; remote cerebrovasc. dis./brain injury: 7 pt.; hydrocephalus
8 pt.; alcohol abuse 10 pt.; drug overdose 11 pt.; head trauma 12 pt.; cryptogenic 12 pt.;
brain tumor 16 pt.; sodium imbalance 17 pt.; metabolic disorders 22 pt.; acute
cerebrovascular dis.: 26 pt.; acute CNS infection: 33 pt.; anoxia: 65 pt.)
Level of consciousness before treatment
2 (alert, somnolent/confused: 0 pt.; stuporous or comatose 1 pt.) 4 (following points did not improve performance: awake 0 pt., somnolence: 5 pt.,
stupor: 14 pt., coma: 23 pt.) [10]
Semiology
3 (simple partial, complex partial, absence, myoclonic-complicating idiopathic
generalized epilepsy: 0 pt.; generalized convulsive 1 pt.; NCSE in coma: 2 pt.)
Not scored, but investigated regarding predictability:
SE with only convulsions: correctly classiﬁed 95.5%,
Seizures including/evolving to NCSE: correctly classiﬁed 81.4%
Duration
Not included 2 (following points did not improve performance: b1 h: 3 pt., N1 h: 33 pt.) [11]
EEG
Not included 5 (burst suppression (spontaneous): 60 pt.; ASIDs 40 pt.; LPDs 40 pt.; GPDs 40 pt.;
no LPDs, GPDs or ASIDs: 0 pt.) [12,13]
Comorbidity
Not included 18 (myocardial infarction, congestive heart failure, peripheral vascular dis.,
cerebrovascular dis., dementia, chronic pulmonary dis., connective tissue dis.,
ulcer disease, mild liver dis., diabetes: 10 pt.; hemiplegia, moderate or severe renal
dis., diabetes with end organ damage, any tumor including leukemia/lymphoma:
20 pt.; moderate or severe liver dis.: 30 pt.; metastatic solid tumor, AIDS: 60 pt.) [14]
LPDs: lateralized periodic discharges, GPDs: generalized per. discharges, ASIDs: after SE discharges, dis.: disease, NCSE: nonconvulsive SE.
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We identiﬁed two scores, i.e., “Status Epilepticus Severity Score —
STESS” [3–5] and “Epidemiology based Mortality score in SE — EMSE”
[6] (Table 1).There is only one study in which STESS with cutoff levels 3 and 4
(STESS-3: 3 or more points indicate bad outcome, i.e., death; STESS-4)
and EMSE (cutoff 64) were applied to one population. In this retrospec-
tive, explorative study, EMSE was signiﬁcantly superior to STESS: nega-
tive predictive value (NPV) of EMSE 100%, STESS-3 82.8% (p= 0.0022),
128 M. Leitinger et al. / Epilepsy & Behavior 49 (2015) 126–130and STESS-4 81.8% (p = 0.00034); positive predictive value (PPV) of
EMSE 68.8%, STESS-3 27.0% (p = 0.000012), and STESS-4 32.4%
(p b 0.00001); correctly classiﬁed (CC) of EMSE 89.1%, STESS-3 44.6%
(p = 0.000029), and STESS-4 62.0% (p b 0.00001); level of signiﬁcance
corrected for multiple testing: p ≤ 0.0044 (Supplementary Fig. 1) [6].
4. Discussion
Status Epilepticus Severity Score and Epidemiology based Mortality
score in SE are the only two available scores for outcome prediction in
SE. Both are easy to apply. Status Epilepticus Severity Score is good at
predicting bad outcome but has a ceiling effect especially in patients
older than 65 years without preexisting epilepsy. In contrast, EMSE is
good at detection of both bad and good outcomes and therefore, is highly
qualiﬁed for individual risk assessment as well as risk stratiﬁcation in
interventional studies. However, EMSE needs prospective evaluation,
because it was developed in a retrospective explorative study, i.e.,
where test results were known. This implies the danger of overﬁtting
the test to the sample from a statistical point of view. However, these
data can be used for fast testing of different hypotheses.
4.1. Concept of “survival limiting process”
Survival is a hard endpoint of outcome.While interpreting results, it
is important to askwhether one particular factor, such as duration of SE,
or the combination of many factors (i.e., EMSE-score, [6]) is or is not the
survival limiting process (SLP). In other words, it depends on the inves-
tigated study population whether a particular parameter is responsible
for death, or just contributes to nonsurvival amongother factors, or does
not play any life-limiting role at all [2].
4.2. Duration and its inherent problems
The correct measurement of duration is hampered by the fact that
the beginning of SE is frequently not witnessed. Furthermore, the
end of SE is also not clear-cut, as diagnosing the end of SE can either
be done by EEG documentation (continuous or intermittent EEG) or
by progressive clinical improvement. With EEG, it is to be deﬁned
whether pathognomonic graphoelements need to be totally eradi-
cated (for how long?) or just “signiﬁcantly reduced”, which is itself
not yet speciﬁed. Alternatively, the progressive improvement in con-
sciousness indicates the end of SE. However, no uniform strategy of
testing has been accepted. We use calling the patient with his ﬁrst
name and asking him to open his eyes, look at the investigator,
count until three, and raise his arms. If the patient is not reactive,
the same procedure is repeated while applying strong tactile stimuli
on each side of the body.
We addressed these issues and developed a data acquisition sheet,
which assures rapid documentation in busy emergency rooms and
availability of data at any time during patient management. It requires
physicians to enter information relevant for calculation of duration as
well as many other important parameters such as level of conscious-
ness, history of seizure semiology, EEG ﬁndings, and appliedmedication
(Supplementary Fig. 2).
An alternative to duration is time to treatment. There is a major dif-
ference between acute treatment of ischemic stroke and SE. In stroke,
the medication (usually recombinant tissue plasminogen activator,
rt-PA) is just adapted to body weight; there is no repetition in case of
failure. Hence, time to treatment seems adequate, as there are no mod-
iﬁcations after initiation. However, in SE, many different medications
are applied in an escalating procedure, which calls for communication
as to when all of these measures were ﬁnally successful, instead of
when they were started. According to these inherent problems, there
are just a few studies reporting the duration instead of time to treat-
ment. The signiﬁcant time points for bad outcome show great variation
depending on the investigated population ranging from 0.5 vs 1 h [15],b 1 h vs N 1 h [11], b2 vs N24 h [16], 2.4 vs 11.2 h [17], b 10 h vs N 10 h
[18], 24 vs 48 h [19], to 88.9 vs 120 h [20]. Interestingly, in a recent ret-
rospective study [20] on 111 patients, duration was markedly
prolonged in nonsurvivors (without reaching statistical signiﬁcance)
with the etiology of “uncontrolled epilepsy”. In this otherwise benign
etiology, it seemed that duration was the only SLP. We speculated
whether some factors (here, duration) “only matter, when nothing
else matters?”. Again, for pathophysiological understanding and tai-
lored therapy, it is mandatory to identify the one or many SLP(s).
4.3. Prediction versus predictability
Semiology was not included as score parameter in EMSE, but results
were investigated concerning semiology. In those patients with “only
convulsive” semiology, i.e., focal motor (FM-SE) or generalized tonic–
clonic (GTC-SE) — both without evolution into nonconvulsive SE
(NCSE), outcome was predictable by EMSE with cases correctly classi-
ﬁed in about 95.6%, as opposed to 81.4% in thosewithNCSE as part of se-
miology, i.e., NCSE as only semiology and FM-SE and GTC-SE — both
evolving into NCSE. It seems that the brain is not the SLP as long as
major motor phenomena are present (only convulsive semiology), as
mortality is predictable by other factors in EMSE. This is congruent
with pathophysiological considerations, where evolution of convulsive
into nonconvulsive semiology is not only associated with a worse prog-
nosis, but also reﬂects the individual sign of cerebral decompensation
with electroclinical dissociation [21,22].
4.4. Level of consciousness (LOC)
Signiﬁcant impact of LOC on survival was ﬁrst reported by Rossetti
et al. [10]. Their data were implemented in EMSE but resulted in no im-
provement of performance [6]. Another study by Rossetti et al. did not
reach signiﬁcance [4]. In NCSE, signiﬁcant differences were reported be-
tween “mild and severe”disturbance of “mental status” [23]. Sutter et al.
found signiﬁcant results for stupor/coma versus awake/somnolence,
which disappeared after exclusion of patients with hypoxia [20]. In
the same study, NCSE-coma was signiﬁcantly associated with bad out-
come, even in the latter population.
4.5. Comorbidities
Data provided by EMSE suggest an important role of comorbidities,
as this is among the successful combination of 4 parameters. This was
in contrast to recent investigationswith elaboratedmodels [24]. Impor-
tantly, another study reported a highly signiﬁcant difference of “Logistic
Organ Dysfunction Score” (LODS) between survivors and nonsurvivors
[25]. Logistic Organ Dysfunction Score summarizes dysfunction of
major organ systems [26]. Therefore, LODS can be interpreted as the
functional consequences of comorbidities, which were scored by
Charlson comorbidity index (CCI) and, therefore, also by EMSE. At the
5th London Innsbruck Colloquium in April 2015 data were presented,
which showed a signiﬁcant role of CCI [27]. Some comorbidity may
have changed its treatability and associated prognosis, such as HIV in-
fections, with signiﬁcant improvements of survival over the past years
[28]. This might also apply to speciﬁc malignancies, where several dis-
eases have a high chance of ﬁve-year progression-free illness. These
changes over time can be implemented easily in EMSE, but should be
done in global interdisciplinary consensus.
4.6. Frequency of periodic discharges
We were able to increase performance of EMSE by including only
lateralized periodic discharges (LPDs) occurring at least at seven
LPDs per ten-second epoch (counted in worst epoch) and generalized
periodic discharges (GPDs) occurring at least at 9 GPDs per 10 s [6].
Whether the rate of periodic discharge is associated with survival
Table 2
Status epilepticus outcome code (SEO-C) allows comprehensive communication of outcome relevant data.
SEMIOLOGY(S)
GTC … generalized tonic-clonic
FM … focal motor
NC … nonconvulsive
NC–ED>2.5… NC with epileptiform discharges more frequent 
than 2.5/s
NC–SCP… NC with subtle clinical phenomena
NC–STE–ED…  NC with spatiotemporal evolution of 
epileptiform discharges in EEG
NC–STE–RDT… NC with spatiotemporal evolution of 
Rhythmical Delta–Theta activity in EEG
NC–ECI… NC with EEG and clinical improvement to iv–AEDs
NC–FED… NC with fluctuation of epileptiform discharges
NC–FRDT… NC with fluctuation of Rhythmical Delta–Theta
NC–OEI… NC with only EEG improvement to iv AEDs 
“/” level of consciousness: w… awake, som…somnolent, 
stp … stuporous, com…comatose  
Example: S (FM GTC NC–STE–ED/stp)  …
SE starting with focal motor activity, transition to 
generalized tonic-clonic convulsions, transition to non
convulsive SE, identified by spatiotemporal evolution of  
epileptiform discharges in EEG while patient was
stuporous
Example extended version:
S (FM: 30 min GTC: 60 min NC–STE–ED/stp: 2 h) … 
Same as above, but with durations of different semiologies
ETIOLOGY (E)
RCV … remote cerebrovascular
ACV … acute cerebrovascular
RTBI … remote traumatic brain injury
ATBI … acute TBI 
EDW… epilepsy, drug withdrawal
AAI … acute alcohol intoxication
AAW … acute alcohol withdrawal
HON … hyponatremia; … other codes to be established
Example: E (RCV)  …  
aetiology is remote cerebrovascular infarction
Example extended version: E (AAW, HON) … 
Patient suffered from acute alcohol withdrawal and  
hyponatremia
AGE (A)
Age in years (yr), for pediatricians: months (mth) or days (d) Example: A (45 yr) … Patient is 45 years old   
THERAPY (T)
B … benzodiazepines
A … antiepileptic drug
N … narcotic
S … measure against superrefractory SE 
Example: T (BA2)  … Treatment with one benzo and 2 AEDs
Example extended version:
T (BA2: LZM 6 (1h), LEV 2000 (1.1h), PHT 1000(1.2 h))…
Details of medication provided together with starting time 
EEG (E)
LPD … lateralised periodic discharges
GPD … generalised periodic discharges 
ASID … after status ictal discharges
SIRPID … stimulus induced rhythmic, periodic or ictal discharges 
STE … typical spatiotemporal evolution
DSL … … diffuse slowing … other codes to be established
Example: E (STE–ED DSL) …   
EEG with spatiotemporal evolution of epileptiform 
discharges, transforming into diffuse slowing
Example extended version: E (STE: R frontal, at 2.5 h) …  
STE was right frontal, EEG was done 2.5 hours from onset
DURATION (D) 
Start: witnessed … stw; not witnessed… snw), “/” 
Duration: 1h (h), day (d), “/”
End diagnosed by:  EEG, progressive clinical  improvement (PCI) 
Example: D (stw/1 h/PCI)  … 
SE with witnessed beginning, lasting for one hour, end was 
diagnosed by progressive clinical improvement
O UTCOME (O)
REST … full restitution to premorbid level
PDEF … survived with persisting deficits 
NOS … nonsurvivor
PEND … pending
Example: O (PEND) … Patient is transferred to tertiary
care centre, outcome pending
Example extended version: O (PDEF: MCS) … Patient  
survived in minimally conscious state
COMORBIDITIES (C)
COPD … chronic obstructive pulmonary disease 
CRF 2… chronic renal failure stage 2   
DM–II… diabetes mellitus type II
CHF … congestive heart failure
CHD … coronary heart disease … other codes to be established
Example: C (CHD, CHF) … Patient suffers from coronary
heart disease and congestive heart failure 
Example: S (FM GTC NC–STE–ED/stp),E(RTBI), A(67 yr), T(BA2),E(STE–ED DSL), D(stw/2h/PCI),  O(REST),C(COPD), 
SE starting with focal motor activity, transition to generalized tonic-clonic convulsions, transition to non–convulsive SE, identified by  
spatiotemporal evolution of ED in EEG while patient was stuporous. Etiology was remote traumatic brain injury. Age was 67 yrs. 
Patient was treated with one benzo and two AEDs. EEG showed spatiotemporal evolution of epileptiform dischargeswith transition 
to diffuse slowing. Start of SE was witnessed, SE lasted 2 hours, end of SE was diagnosed by progressive clinical improvement.  
Outcome was restitution to premorbid level. Comorbidity was chronic obstructive pulmonary disease.
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achieved, when after SE ictal discharges (ASIDs) were not included, but
numbers were too small to draw ﬁrm conclusions [6].
4.7. Adequate reporting of outcome scores in studies
Group effects are adequately reported as statistically signiﬁcant as-
sociations. Outcome scores (OS) are derived from these group effects
and are, therefore, intrinsically associatedwith theunderlying condition
(Supplementary Fig. 3). Hence, it is not enough to demonstrate the sta-
tistically signiﬁcant association of OS with clinical condition. Rather, the
benchmark for OS is the rate of correctly classiﬁed cases, negative and
positive predictive values in the investigated population, and further
sensitivity and speciﬁcity.
4.8. Status epilepticus outcome code (SEO-C)
We searched for a measure to enhance (1) usage of scores for indi-
vidual risk assessment for individually tailored therapy, (2) entrance
of patient-speciﬁc data into epidemiological studies and registries and
further into public health projects, and (3) support communication in
case of patient transfer or discharge, or in case of regular staff rotation
between day and night shifts (Supplementary Fig. 3). We developed
SEO-C to address these issues with a basic and an extended version
(Table 2) and, hereby, gave answer to the call for an international
reporting standard for SE ﬁrst raised by R. Dieckmann in 2006 [28].
Feasibility of SEO-C is not yet published.
5. Conclusion
Epidemiology based Mortality score in SE needs prospective valida-
tion. So far, EMSE qualiﬁes for risk stratiﬁcation in interventional studies
and is recommended for individual outcome prediction. A speciﬁc code
for collecting SE related data in clinical practice (SEO-C) is proposed.
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